Immunogenicity of Rabies Vaccine Booster Doses in Schoolchildren
Author Information
Author(s): Kamoltham Thavatchai, Thinyounyong Wiravan, Khawplod Pakamatz, Phraisuwan Phran, Phongchamnaphai Phana, Anders Gerlind, Malerczyk Claudius
Primary Institution: Office of Permanent Secretary, Ministry of Health, Thailand
Hypothesis
The study aims to assess the immunogenicity of intradermal booster doses of rabies vaccine administered to schoolchildren after primary vaccination.
Conclusion
The study found that the rabies vaccine is safe and effective in eliciting an immune response in schoolchildren even five years after initial vaccination.
Supporting Evidence
- 100% of children developed adequate rabies virus neutralizing antibody concentrations after booster doses.
- An approximately 30-fold increase in RVNA concentrations was observed within 14 days after the booster.
- No serious adverse events related to the vaccine were reported.
Takeaway
The rabies vaccine works well for kids, even years after they first got it, and they can get booster shots safely.
Methodology
This was a follow-up study of a randomized, open-label, phase II clinical trial where two booster doses of rabies vaccine were given to schoolchildren one, three, or five years after primary vaccination.
Limitations
The study did not include a control group of unvaccinated children for comparison.
Participant Demographics
Healthy schoolchildren aged 5 to 8 years at the time of primary vaccination.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website